Sigma Of Australia To Report U.S.$254 Million Loss From Past Buys
This article was originally published in PharmAsia News
Executive SummaryAustralia's Sigma Pharmaceuticals, reeling from acquisitions it made several years ago, is expected to report a loss for the past year of more than U.S.$254 million
You may also be interested in...
Alnylam’s Givlaari for acute hepatic porphyria is also among the 14 new products that could get an EU approval recommendation this week.